| Votrient (pazopanib) / Novartis, BeiGene |
NCT01975519: A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma |
|
|
| Completed | 2a | 111 | US | TRC105 and Pazopanib, Chimeric Antibody (TRC105) to CD105, Votrient | Tracon Pharmaceuticals Inc. | Advanced Soft Tissue Sarcoma | 03/19 | 03/19 | | |
|
|
|
|
jRCTs031190152: JCOG1802: A randomized phase II trial of 2nd line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib |
|
|
| Active, not recruiting | 2 | 120 | Japan | Yondelis (trabectedin) - Otsuka, PharmaMar, Valeo Pharma, J&J, Halaven (eribulin mesylate) - Eisai, Votrient (pazopanib) - Novartis, BeiGene | Oita University Hospital, National Cancer Center Japan,Japan Agency for Medical Research and Development | Advanced soft tissue sarcoma | | | | |
NCT00459381: Pazopanib in Treating Patients With Recurrent Glioblastoma |
|
|
| Completed | 2 | 35 | US | pazopanib hydrochloride, GW786034B, Votrient, laboratory biomarker analysis | National Cancer Institute (NCI) | Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor | 12/08 | 12/08 | | |
NCT01391611: Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) |
|
|
| Terminated | 2 | 25 | US | Pazopanib, Votrient | Kristen Ganjoo, GlaxoSmithKline | Gastrointestinal Stromal Tumor (GIST) | 06/13 | 12/13 | | |
NCT00297258: Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma |
|
|
| Completed | 2 | 148 | Europe | pazopanib, GW786034 | GlaxoSmithKline | Sarcoma, Soft Tissue | 02/14 | 02/14 | | |
2004-004378-10: Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists. |
|
|
| Completed | 2 | 148 | Europe | GW786034, GW786034, Tablet | GlaxoSmithKline Research & Development Ltd | Advanced and/or metastatic Soft Tissue Sarcoma | | | | |
| Terminated | 2 | 23 | Europe | Pazopanib | Assistance Publique - Hôpitaux de Paris, GlaxoSmithKline | Dermatofibrosarcomas of DARIER FERRAND(DFSP) | 04/14 | 04/14 | | |
| Completed | 2 | 81 | Europe | Pazopanib, Best supportive care | Centre Leon Berard, GlaxoSmithKline | GIST | 04/14 | 02/16 | | |
|
| Terminated | 2 | 31 | Europe | Pazopanib, Votrient | Cambridge University Hospitals NHS Foundation Trust, University of Cambridge | Renal Cell Carcinoma, Soft Tissue Sarcoma, Glioblastoma, Ovarian Cancer, Cervical Cancer, Breast Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreatic Cancer, Melanoma, Gastrointestinal Cancer | 09/14 | 09/15 | | |
NCT01506596: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma |
|
|
| Completed | 2 | 42 | US | pazopanib, Votrient | Vector Oncology, Novartis | Liposarcoma, Surgically Unresectable Liposarcoma, Metastatic Liposarcoma | 10/14 | 03/16 | | |
| Completed | 2 | 72 | Europe | Pazopanib, Votrient | Scandinavian Sarcoma Group, GlaxoSmithKline | Gastrointestinal Stromal Tumors | 01/15 | 11/16 | | |
2010-022416-40: A Translational, proof of the concept, study Of Pre-operative Pazopanib in treatment-naive patients with resectable soft tissue Sarcomas (TOPPS) |
|
|
| Ongoing | 2 | 30 | Europe | pazopanib, Votrient, Votrient | The Royal Marsden NHS Foundation Trust | Resectable Soft Tisue Sarcomas (cancer of conective soft tissues) | | | | |
| Ongoing | 2 | 35 | Europe, RoW | Pazopanib, votrient | The Netherlands Cancer Institute, The Netherlands Cancer Institute | soft tissue sarcoma, sarcoma/cancer, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT01247571: Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer |
|
|
| Completed | 2 | 22 | US | Pazopanib Hydrochloride, GW786034B, Votrient | National Cancer Institute (NCI), NRG Oncology | Recurrent Uterine Corpus Sarcoma, Uterine Carcinosarcoma | 01/16 | 01/16 | | |
2009-017261-32: Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma |
|
|
| Completed | 2 | 90 | Europe | Gemcitabine, Gemcitabine, Film-coated tablet, Concentrate for solution for infusion, Votrient 400 mg film-coated tablets, Votrient 200 mg film-coated tablets | Martin-Luther-Universität Halle-Wittenberg, GlaxoSmithKline GmbH & Co.KG, Aspen Bad Oldesloe GmbH, Martin Luther Universität Halle (Saale) | Relapsed or metastatic soft tissue sarcoma, Relapsed or metastatic soft tissue sarcoma, Diseases [C] - Cancer [C04] | | | | |
| Terminated | 2 | 1 | Europe | Pazopanib, Votrient, Placebo (for Pazopanib) | Ludwig-Maximilians - University of Munich | Sarcoma | 07/16 | 07/16 | | |
NCT02113826: Pazopanib for Metastatic Alveolar Soft Part Sarcoma |
|
|
| Terminated | 2 | 6 | RoW | Pazopanib | Seoul National University Hospital, Seoul National University Bundang Hospital, Asan Medical Center, Samsung Medical Center, Severance Hospital | Metastatic Alveolar Soft Part Sarcoma | 09/16 | 11/17 | | |
| Terminated | 2 | 21 | Europe | pazopanib, Votrient | Heidelberg University, Universitätsmedizin Mannheim, Klinikum Frankfurt Höchst, German Cancer Research Center, GlaxoSmithKline, University Hospital Heidelberg | Sarcoma, Soft-tissue | 10/16 | 10/16 | | |
NCT01759303: Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung |
|
|
| Terminated | 2 | 12 | US | pazopanib, Votrient | George Clinical Pty Ltd, Novartis | Osteosarcoma, Metastatic Osteosarcoma | 01/17 | 05/17 | | |
NCT01861951 / 2011-004168-30: A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma |
|
|
| Completed | 2 | 120 | Europe | Pazopanib, Doxorubicin | Hannover Medical School | Soft Tissue Sarcoma | 07/17 | 07/17 | | |
NCT03149120: Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas |
|
|
| Withdrawn | 2 | 0 | US | Nivolumab, Opdivo, Pazopanib, Votrient | NYU Langone Health, Bristol-Myers Squibb | Soft Tissue Sarcomas | 08/17 | 06/22 | | |
| Withdrawn | 2 | 0 | US | Pazopanib | Gynecologic Oncology Group, GlaxoSmithKline | Uterine Leiomyosarcoma | 01/18 | | | |
| Completed | 2 | 47 | Europe, US | pazopanib, Votrient | George Clinical Pty Ltd, GlaxoSmithKline | Chondrosarcoma, Metastatic Chondrosarcoma | 02/18 | 02/18 | | |
NCT01442662: Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine |
|
|
| Completed | 2 | 106 | Europe | pazopanib + gemcitabine | UNICANCER | Leiomyosarcoma | 03/18 | 05/19 | | |
| Completed | 2 | 52 | Europe | Pazopanib | Grupo Espanol de Investigacion en Sarcomas, GlaxoSmithKline | Advanced and / or Metastatic Liposarcoma | 03/18 | 03/18 | | |
NCT02357810: Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas |
|
|
| Completed | 2 | 178 | US | Pazopanib Hydrochloride, GW786034B, Votrient, Oral Topotecan Hydrochloride, Hycamtin Capsules, Oral Hycamtin, Laboratory Biomarker Analysis | Northwestern University, GlaxoSmithKline, National Cancer Institute (NCI) | Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Liposarcoma, Recurrent Osteosarcoma, Stage IV Adult Soft Tissue Sarcoma | 04/18 | 10/21 | | |
NCT02367651: Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma |
|
|
| Withdrawn | 2 | 0 | US, RoW | Pazopanib 800 mg, Placebo | GlaxoSmithKline | Sarcoma, Soft Tissue | 05/18 | 05/18 | | |
NCT02601209: Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma |
|
|
| Terminated | 2 | 151 | US | Pazopanib, GW786034, Pazopanib Hydrochloride, GW786034B, Votrient, Sapanisertib, INK-128, INK128, MLN-0128, MLN0128, TAK-228 | National Cancer Institute (NCI) | High Grade Sarcoma, Metastatic Leiomyosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Unresectable Sarcoma, Myxofibrosarcoma, Recurrent Leiomyosarcoma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Synovial Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma | 12/18 | 07/22 | | |
NCT01462630: Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma |
|
|
| Completed | 2 | 29 | US | pazopanib hydrochloride, GW786034B, Votrient, laboratory biomarker analysis, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, computed tomography, tomography, computed, fludeoxyglucose F 18, 18FDG, FDG | Fox Chase Cancer Center, National Cancer Institute (NCI) | Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma | 01/19 | 01/21 | | |
NCT01767636: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer |
|
|
| Active, not recruiting | 2 | 38 | US | Pazopanib Hydrochloride, GW786034B, Votrient | Mayo Clinic, National Cancer Institute (NCI) | Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma, Metastatic Renal Cell Cancer, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer | 02/19 | 11/24 | | |
PASART-2, NCT02575066: Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients |
|
|
| Terminated | 2 | 25 | Europe | external beam radiotherapy, radiotherapy, pazopanib | The Netherlands Cancer Institute, Royal Marsden NHS Foundation Trust | Sarcoma, Soft Tissue Sarcomas | 03/19 | 03/19 | | |
NCT01593748: A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma |
|
|
| Completed | 2 | 90 | US | Gemcitabine and Pazopanib, Gemcitabine and Docetaxel | Medical University of South Carolina, Novartis | Sarcoma | 04/19 | 04/19 | | |
NCT02300545: Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy |
|
|
| Completed | 2 | 56 | US | Pazopanib, GW786034, Votrien | Washington University School of Medicine, Novartis Pharmaceuticals | Sarcoma, Soft Tissue, Soft Tissue Sarcoma | 05/19 | 07/20 | | |
NCT01931098: Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab |
|
|
| Completed | 2 | 35 | US | topotecan, Hycamtin, pazopanib, Votrient | National Cancer Institute (NCI) | Glioblastoma, Glioblastoma Multiforme, Gliosarcoma, Brain Neoplasms, Central Nervous System Neoplasms | 09/19 | 09/19 | | |
NCT01532687: Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma |
|
|
| Completed | 2 | 54 | US | Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pazopanib, GW786034, Pazopanib Hydrochloride, GW786034B, Votrient, Placebo Administration | OHSU Knight Cancer Institute, Novartis Pharmaceuticals, Oregon Health and Science University | Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated Pleomorphic Sarcoma, Malignant Adult Hemangiopericytoma, Recurrent Adult Soft Tissue Sarcoma, Sarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7 | 10/19 | 10/19 | | |
| Completed | 2 | 96 | Europe | Pazopanib, Votrient | Grupo Espanol de Investigacion en Sarcomas | Solitary Fibrous Tumor, Extraskeletal Myxoid Chondrosarcoma | 12/19 | 03/23 | | |
| Terminated | 2 | 26 | Europe | Pazopanib + Paclitaxel | Heidelberg University, Universitätsmedizin Mannheim, Helios Klinikum Berlin-Buch, University Hospital Dresden, Universitätsklinikum Hamburg-Eppendorf, University Hospital, Essen, Hannover Medical School, Klinikum der Universitaet Muenchen, Grosshadern, Medical University of Vienna, Medical University of Graz, Medical University Innsbruck, Novartis Pharmaceuticals | Angiosarcoma | 12/19 | 07/20 | | |
NCT02342600: SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) |
|
|
| Withdrawn | 2 | 0 | NA | Pazopanib, Votrient, Trametinib, Mekinist | Sarcoma Alliance for Research through Collaboration, Novartis | Gastrointestinal Stromal Tumors | 01/20 | | | |
NCT01664182: Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer |
|
|
| Completed | 2 | 41 | US | Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Pazopanib Hydrochloride, GW786034B, Votrient, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib, Sunitinib Malate, SU011248, SU11248, sunitinib, Sutent, Trebananib, AMG 386, AMG386, Angiopoietin 1/2-Neutralizing Peptibody AMG 386 | National Cancer Institute (NCI) | Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7 | 12/20 | 12/20 | | |
|
NCT03798106: A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma |
|
|
| Completed | 2 | 46 | RoW | Durvalumab, pazopanib | Yonsei University | Sarcoma | 08/22 | 08/22 | | |
| Active, not recruiting | 2 | 58 | Europe | Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient | North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH | Leiomyosarcoma or Carcinosarcoma | 12/24 | 12/24 | | |
NCT05679921: Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma |
|
|
| Not yet recruiting | 2 | 116 | NA | pembrolizumab, pazopanib | Yonsei University | Soft Tissue Sarcoma | 12/26 | 12/26 | | |
NCT01719302: Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma |
|
|
| Completed | 1/2 | 6 | US | Gemcitabine, Gemzar, Docetaxel, Taxotere, Pazopanib, Votrient | University of Vermont, Novartis | Stage III Adult Soft Tissue Sarcoma | 04/15 | 04/15 | | |
NCT01418001: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) |
|
|
| Terminated | 1/2 | 5 | US | Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination | Memorial Sloan Kettering Cancer Center, National Comprehensive Cancer Network, University of California, Los Angeles, Washington University School of Medicine, Northwestern University | Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous, Histiocytoma/Undifferentiated Pleomorphic Sarcoma | 11/15 | 11/15 | | |
NCI-2018-01624, NCT03660930: Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas |
|
|
| Active, not recruiting | 1/2 | 19 | US | Sirolimus Albumin-bound Nanoparticles, Nab-Rapamycin, Nanoparticle Albumin-Bound Rapamycin, ABI-009, Nanoparticle Albumin-bound Sirolimus, Fyarro, Sirolimus Protein-bound Particles, Pazopanib hydrochloride, Votrient | University of Washington, Aadi Bioscience, Inc. | Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma | 11/22 | 02/25 | | |
NCT06239272: NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) |
|
|
| Recruiting | 1/2 | 139 | US | Surgical resection, Proton beam radiation therapy, Pazopanib, VOTRIENT®, Ifosfamide, Ifex, Doxorubicin, Adriamycin®, Rubex®, Selinexor, XPOVIO® | St. Jude Children's Research Hospital | Non-rhabdomyosarcoma, Adipocytic Neoplasm, Liposarcoma | 06/34 | 06/37 | | |
AMPHISARC, NCT05180695: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas |
|
|
| Recruiting | 1/2 | 58 | Europe | Pazopanib, Votrient, HDM201, siremadlin | Centre Leon Berard, Novartis, National Cancer Institute, France | Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | 01/26 | 07/26 | | |
